YARON NAOS

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Protalix BioTherapeutics, Inc.

Filing Date Source Excerpt
2018-10-17 Yaron Naos(6)
2019-10-15 Security Ownership of Certain Beneficial Owners and Management table
2021-09-30 Yaron Naos Consists of 19,955 outstanding shares of our common stock and 88,330 shares of our common stock issuable upon exercise of outstanding options

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-08